Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) released its quarterly earnings results on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.12), Zacks reports. Verrica Pharmaceuticals had a negative return on equity of 3,102.90% and a negative net margin of 625.06%. The business had revenue of ($1.78) million during the quarter, compared to the consensus estimate of $7.53 million.

Verrica Pharmaceuticals Trading Up 6.9 %

NASDAQ VRCA traded up $0.05 on Wednesday, hitting $0.85. 539,683 shares of the stock were exchanged, compared to its average volume of 448,631. The company has a market capitalization of $36.37 million, a price-to-earnings ratio of -0.44 and a beta of 1.45. Verrica Pharmaceuticals has a 52-week low of $0.75 and a 52-week high of $11.41. The company has a debt-to-equity ratio of 29.58, a current ratio of 2.36 and a quick ratio of 2.23. The company’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $5.17.

Wall Street Analysts Forecast Growth

VRCA has been the subject of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday. HC Wainwright lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $11.00 to $2.00 in a research note on Tuesday. Finally, TD Cowen decreased their price target on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.60.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.